Talks (437)
chemo prevention and breast cancer
Dec 31
treating micromets in breast cancer
Dec 31
radiosensitization in breast cancer
Dec 31
cdk46 in first line mbc and os
Dec 31
tdxd and ild
Dec 31
benefit of cdk46 in subtypes of er+
Dec 31
ODAC evaluation of PFS IN CODEBREAK200
Dec 29
Tofacitinib in refractory ICI hepatitis
Dec 27
BMS acquires Rayzebio
Dec 26
KN 585 now published
Dec 20
Capivasertib in mBC
Dec 20
Olanzapine in cancer patients
Dec 18
Olanzapin in cancer patients
Dec 18
VTE prophylactic
Dec 18
ADCs
Dec 18
Palliative Care
Dec 18
Ev Pembro FDA approval
Dec 17
Belzutifan approved for RCC
Dec 15
FDA approval of enfortumab/pembro for UC
Dec 15
Belzutifan FDA approval RCC
Dec 15
NPC
Dec 14
Neuroblastoma
Dec 14
delay CAR-T in privately insured pts
Dec 14
HER2 positive mUC
Dec 08
Breast Cancer
Dec 07
Breast Cancer
Dec 07
Breast Cancer
Dec 07
Breast Cancer
Dec 07
NSCLC
Dec 04
NSCLC
Dec 04
Triplet therapy in mRCC
Dec 01
DANTE trial
Nov 30
Nirogacestat FDA approval
Nov 30
Pembro in Cholangiocarcinomq
Nov 30
Ultraprocessed food and risk of cancer
Nov 30
FDA approves pembro based off KN689
Nov 29
EMERALD-1 positive
Nov 29
Pembro plus Chemo GEJ cancers
Nov 28
Fruquintinib in mCRC
Nov 28
Ropotrectinib FDA APPROVAL
Nov 28
FDA Approval for Enza in nmCSPS with BCR
Nov 23
Erdafitinib Vs Chemo in mUC
Nov 23
ENZA-p
Nov 23
public health
Nov 21
Her-2 Tumors
Nov 21
lung cancer
Nov 21
extenet trial
Nov 19
dato dxd in HR pos MBC
Nov 19
ADCs in MBC
Nov 19
capivasertib in HR pos MBC
Nov 19
adj therapy in high risk her2 pos BC
Nov 19
should we use IO in HR pos early BC?
Nov 19
immunotherapy in HR+ early BC
Nov 19
HNSCC
Nov 15
SCLC
Nov 15
Mesothelioma
Nov 15
CRC
Nov 15
Lung Cancer
Nov 15
Fruquintinib FDA approved for mCRC
Nov 09
IO
Nov 09